This is to let you know that the PARP inhibitor rucaparib has been approved by NICE for use in the Cancer Drugs Fund. It can now be offered to people with relapsed ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.
Your treating team will be able to advise you about whether rucaparib would be suitable for you. If there's anything we can help with, please get in touch with our Support Service on 0800 008 7054 or by email at support@ovacome.org.uk.
Best wishes
Julia (Support Services Officer)
Written by
OvacomeSupport
Partner
To view profiles and participate in discussions please or .
This is very welcome good news, especially as it is available to non BRCA ladies, and you can still have it if you only had a partial response to Platinum.
Thank you for the information. Is this approval subject to the same conditions as Niraparib -- i.e., that it must be started within 12 weeks of finishing successful platinum chemo? Does it depend on BRCA or other genetic indicator? Gill
The recommendation is that it is started within 8 weeks of chemotherapy, when someone has responded to platinum chemotherapy. It isn't dependent on BRCA status. You can read the NICE final appraisal document here: nice.org.uk/guidance/gid-ta...
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
